Co-Authors
This is a "connection" page, showing publications co-authored by Gesine Meyer-Rath and Ian Sanne.
Connection Strength
0,783
-
The Role of Remdesivir in South Africa: Preventing COVID-19 Deaths Through Increasing Intensive Care Unit Capacity. Clin Infect Dis. 2021 05 04; 72(9):1642-1644.
Score: 0,193
-
Changing the South African national antiretroviral therapy guidelines: The role of cost modelling. PLoS One. 2017; 12(10):e0186557.
Score: 0,152
-
Attrition through multiple stages of pre-treatment and ART HIV care in South Africa. PLoS One. 2014; 9(10):e110252.
Score: 0,123
-
The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One. 2012; 7(5):e36966.
Score: 0,104
-
Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa. Open Forum Infect Dis. 2021 Mar; 8(3):ofab040.
Score: 0,047
-
Cost-effectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa. medRxiv. 2020 Sep 27.
Score: 0,046
-
Citizenship status and engagement in HIV care: an observational cohort study to assess the association between reporting a national ID number and retention in public-sector HIV care in Johannesburg, South Africa. BMJ Open. 2017 01 24; 7(1):e013908.
Score: 0,036
-
Impact and costs of algorithms for the diagnosis of adults with pulmonary tuberculosis in South Africa. S Afr Med J. 2013 Jul; 103(7):436.
Score: 0,028
-
Diagnosing Xpert MTB/RIF negative TB: impact and cost of alternative algorithms for South Africa. S Afr Med J. 2013 Jan 14; 103(2):101-6.
Score: 0,027
-
Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa. Trop Med Int Health. 2012 Sep; 17(9):1142-51.
Score: 0,026